FDA 483 - Catalent Greenville Inc - October 24, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
The FDA inspected Catalent Greenville Inc, a contract drug manufacturer, and issued a Form 483 with three observations. The inspection revealed significant issues across equipment maintenance, microbial testing, and stability program adherence, indicating potential risks to drug product quality and safety. Specifically, observations included unvalidated equipment modifications, worn equipment, inadequate microbial testing and identification, and poor control over stability samples.
ID · 4533beac-cc6a-41f8-8d08-00ecde98205c